ClinicalTrials.gg
Not yet recruitingNCT07948655Thy-CVD CohortUpdated Nov 19, 2026

Thyroid Function and Cardiovascular Disease: The Thy-CVD Cohort

An observational study in Thyroid Dysfunction, Hyperthyroidism and Cardiovascular Diseases, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Hyperthyroidism with a site in China — 4 open to participants now, 5 under way, none of them phase 3. Hyperthyroidism · China.

Started
2026
the only one that year
Observational
8 of 12
4 open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
First Affiliated Hospital Xi'an Jiaotong University

Among the 12 studies in Hyperthyroidism with a site in China, this one is the only one that started in 2026, is one of 8 observational ones, and was the 12th registered.

Hyperthyroidism

113 studies on the registry are indexed under Hyperthyroidism; 27 are open to participants now.

Browse Hyperthyroidism studies →

Open to participants now

4 of the 12 studies in Hyperthyroidism with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 17 Hyperthyroidism studies recruiting now, 8 (47%) set no upper age limit and 7 (41%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hyperthyroidism with a site in China, or all of them as a file.
02

Study summary

The goal of this multicenter observational study is to investigate the relationship between thyroid function, changes in thyroid hormone levels over time, and cardiovascular diseases in adults. The main questions it aims to answer are:

Are different thyroid function states and long-term changes in thyroid hormone levels associated with the risk of major adverse cardiovascular events? How do thyroid function abnormalities affect cardiac structure and function, and can these changes improve after thyroid function returns to normal? Researchers will compare participants with normal thyroid function, subclinical thyroid dysfunction, and overt thyroid dysfunction to evaluate differences in cardiovascular outcomes.The study includes retrospective and prospective cohorts. Researchers will collect thyroid function tests, clinical records, electrocardiograms, echocardiographic findings, treatment information, and long-term cardiovascular outcomes. Participants in the prospective cohort will undergo follow-up, with biological samples collected for exploratory analyses when appropriate and with informed consent. No experimental treatments will be assigned.

Read the detailed description

The Thy-CVD Cohort is a nationwide, multicenter, observational study combining retrospective and prospective cohorts to investigate the associations of thyroid function abnormalities and dynamic thyroid hormone exposure with cardiac remodeling and long-term cardiovascular outcomes.The study will enroll adults aged 18 years or older with available thyroid function testing. Participants will be classified into five groups according to thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), and free thyroxine (FT4) levels: euthyroidism, subclinical hyperthyroidism, overt hyperthyroidism, subclinical hypothyroidism, and overt hypothyroidism.The retrospective cohort will include patients evaluated between January 2018 and August 2026. The prospective cohort will enroll participants beginning in September 2026, with standardized longitudinal follow-up planned through 2036.Repeated thyroid function measurements will be used to evaluate the severity, duration, variability, and cumulative burden of thyroid hormone abnormalities, as well as the time required to achieve and maintain normal thyroid function.The primary outcome is the first occurrence of a composite major adverse cardiovascular event, including cardiovascular death, hospitalization for heart failure, myocardial infarction, ischemic or hemorrhagic stroke, and serious arrhythmias requiring clinical intervention.Secondary outcomes include individual cardiovascular events, all-cause mortality, and changes in cardiac structure and function assessed by serial echocardiography. The study will also investigate cardiac reverse remodeling and residual cardiovascular risk after normalization of thyroid function.Exploratory analyses will evaluate associations between thyroid treatment strategies, thyroid function control, and cardiovascular outcomes. Biological samples and clinically obtained residual cardiovascular tissues may be analyzed in selected participants to investigate potential molecular mechanisms.This is an observational study. All clinical treatments and examinations will be determined by treating physicians according to routine clinical practice, without investigator-assigned interventions.

03

Conditions studied

  • Thyroid Dysfunction
  • Hyperthyroidism
  • Cardiovascular Diseases
  • Hypothyroidism

Keywords

  • Thyroid function
  • Thyroid-stimulating hormone
  • Free thyroxine
  • Cardiac remodeling
  • Time-varying exposure
  • Ambidirectional cohort
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged 18 years or older who undergo thyroid function testing at the First Affiliated Hospital of Xi'an Jiaotong University and participating medical centers across China. The study population includes individuals with normal thyroid function, subclinical hyperthyroidism, overt hyperthyroidism, subclinical hypothyroidism, and overt hypothyroidism. The retrospective cohort includes eligible patients identified from existing medical records between January 2018 and August 2026. The prospective cohort consecutively enrolls eligible participants beginning in September 2026 for longitudinal follow-up. Thyroid function status, cardiovascular risk factors, treatment information, cardiac imaging findings, and clinical outcomes will be collected. Biological sample availability is not required for enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 years or older.
  2. At least one thyroid function assessment, including thyroid-stimulating hormone (TSH) and free triiodothyronine (FT3) and/or free thyroxine (FT4).
  3. Available and traceable clinical information, including demographic characteristics, medical history, laboratory findings, imaging results, or follow-up records.
  4. Thyroid functional status can be determined from available thyroid function measurements and corresponding laboratory reference ranges.
  5. For the prospective cohort, participants must provide for study participation and be willing to undergo longitudinal follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Thyroid functional status cannot be reliably determined from available clinical and laboratory data.
  2. Key clinical information is substantially incomplete or unreliable, preventing adequate assessment of the primary outcome.
  3. No reliable information is available to ascertain cardiovascular outcomes or vital status after baseline.
  4. Duplicate enrollment; only the first eligible record will be retained.
  5. Other circumstances that, in the investigator's judgment, make the individual unsuitable for study participation or long-term follow-up.

Biospecimen availability is not required for enrollment. Participants without available biological samples remain eligible if they meet the other inclusion and exclusion criteria.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
10,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Retrospective Cohort

    Adults aged 18 years or older who underwent thyroid function testing at participating centers between January 2018 and August 2026 will be retrospectively identified through existing electronic health records. Clinical data, including thyroid function measurements (TSH, FT3, and FT4), thyroid disease diagnoses, treatment history, cardiovascular risk factors, electrocardiographic and echocardiographic findings, and clinical outcomes, will be collected from existing medical records and follow-up databases. Participants will be classified according to baseline thyroid function status and longitudinal thyroid hormone exposure patterns, where repeated measurements are available. No additional clinical interventions will be performed.

  • Prospective Cohort

    Adults aged 18 years or older undergoing thyroid function testing at participating centers will be prospectively enrolled beginning in September 2026 and followed longitudinally. Baseline and follow-up data will include thyroid function measurements (TSH, FT3, and FT4), thyroid disease characteristics, treatment information, cardiovascular risk factors, electrocardiographic and echocardiographic findings, and clinical outcomes. Repeated thyroid function assessments will be used to characterize longitudinal hormone exposure patterns and their associations with cardiac remodeling and cardiovascular events. Biological samples may be collected with informed consent for exploratory analyses. Clinical management will follow routine medical practice without investigator-assigned interventions.

06

What researchers measure

Primary outcomes

  1. Time to First Major Adverse Cardiovascular Event (MACE)

    Time from baseline to the first occurrence of major adverse cardiovascular events (MACE), defined as the composite of cardiovascular death, hospitalization for heart failure, myocardial infarction, ischemic or hemorrhagic stroke, or serious arrhythmia requiring clinical intervention, including new-onset atrial fibrillation and sustained ventricular arrhythmias. The outcome will be measured as time to the first qualifying event in days. Events will be identified through medical records, hospitalizations, clinical follow-up, and available death records. Only the first qualifying event per participant will be counted.

    Time frame: Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.

Secondary outcomes

  1. New-Onset Atrial Fibrillation

    Number of participants without documented atrial fibrillation at baseline who develop newly diagnosed atrial fibrillation during follow-up. Atrial fibrillation will be identified by 12-lead electrocardiography, ambulatory electrocardiographic monitoring, or documented clinical diagnoses in medical records. The outcome will be reported as the number of participants with newly diagnosed atrial fibrillation.

    Time frame: Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.

  2. Heart Failure Events

    Number of participants experiencing clinically documented heart failure events during follow-up. Heart failure will be identified through physician-documented diagnoses, hospitalization records, and available clinical assessments. The outcome will be reported as the number of participants with documented heart failure events.

    Time frame: Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.

  3. Coronary Artery Disease Events

    Number of participants experiencing clinically documented coronary artery disease events during follow-up. Events will be identified from medical records, clinical diagnoses, coronary angiography, and available coronary imaging reports. The outcome will be reported as the number of participants with documented coronary artery disease events.

    Time frame: Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2046, 236 months later.

Of 20 observational studies under Hyperthyroidism, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's planned 236 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 19, 2026
StartEst.
Nov 11, 2026
Primary completionEst.
Aug 1, 2046
CompletionEst.
Aug 1, 2046
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07948655
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Nov 11, 2026 (estimated)
Primary completion
Aug 1, 2046 (estimated)
Completion
Aug 1, 2046 (estimated)
Last update
Nov 19, 2026

Study contacts

Guoliang Li
Contact
guoliangli@xjtu.edu.cn
0086-2985323868
Yang Yan
Contact
yangyan3@xjtu.edu.cn
0086-2985323865
Guoliang Li
principal investigator · First Affiliated Hospital Xi'an Jiaotong University
Yang Yan
principal investigator · First Affiliated Hospital Xi'an Jiaotong University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion